Navigation Links
Range of diagnostic spinal fluid tests needed to differentiate concurrent brain diseases
Date:4/20/2012

NEW ORLEANS Teasing out the exact type or types of dementia someone suffers from is no easy task; neurodegenerative brain diseases share common pathology and often co-occur. Researchers from the Perelman School of Medicine at the University of Pennsylvania are continuing efforts to differentiate diseases, such as Alzheimer's disease (AD) from frontotemporal lobar degeneration (FTLD), as FTLD is often clinically difficult to distinguish from atypical presentations of AD.

In a series of studies being presented at the American Academy of Neurology's 64th Annual Meeting in New Orleans, Penn researchers demonstrated that, while tests created for AD are effectively diagnosing the condition when it's clear cut, additional tests are needed to address the many cases with mixed pathology.

"With the emergence of disease-modifying treatments for AD and other neurodegenerative diseases, it will be of utmost importance to accurately identify the underlying neuropathology in patients," said senior author John Q. Trojanowski, MD, PhD, professor of Pathology and Laboratory Medicine and co-director of the Center for Neurodegenerative Disease Research at Penn.

In one study, the Penn team compared results of a test looking at levels of tau and amyloid beta (Aβ) in the spinal fluid, using two different types of analytical platforms. They determined that values from the two platforms could effectively be transformed into equivalent units, and these values accurately distinguished AD from FTLD. A cutoff of 0.34 for the t-tau:Aβ1-42 ratio had 90 - 100 percent sensitivity and 91-96.7 percent specificity to differentiate FTLD cases, respectively.

In another study, the team looked at patient cases with more than one underlying neurodegenerative disease and compared the accuracy of the biomarkers using clinical and neuropathological diagnosis. They determined that cerebral spinal fluid (CSF) Aβ and tau assays provided a valid diagnosis of AD but, in mixed pathology cases where Alzheimer's was present along with other diseases (confirmed by autopsy), the testing strategies classified the diagnosis as AD alone.

"We need to develop better CSF diagnostic panels for the early diagnosis of neurodegenerative dementias, including those due to mixed neurodegenerative disease pathologies that commonly co-occur with Alzheimer's," said senior author Murray Grossman, MD, professor of Neurology and director of the Penn FTLD Center.

The two posters will be presented during the American Academy of Neurology's 64th Annual Meeting:

Monday, April 23, 2012 10:00 AM
[IN3-1.010] Improving Diagnostic Accuracy for Dementia: CSF Biomarker Cutoffs Based on Clinical and Neuropathological Criteria
Jon B. Toledo, Philadelphia, PA, Johannes Brettschneider, Ulm, PA, Murray Grossman, Steven Arnold, Philadelphia, PA, William Hu, Atlanta, GA, Sharon X. Xie, Virginia M. Y. Lee, Leslie Shaw, John Trojanowski, Philadelphia, PA

Tuesday, April 24, 2012 7:30 AM
[P02.055] Comparison of Cerebrospinal Fluid Levels of Tau and Aβ1-42 in Alzheimer's Disease and Frontotemporal Degeneration Using Two Analytical Platforms
David Irwin, Corey T. McMillan, Jon B. Toledo, Steven Arnold, Leslie Shaw, Li-San Wang, Virginia Lee, John Trojanowski, Murray Grossman, Philadelphia, PA


'/>"/>

Contact: Kim Menard
kim.menard@uphs.upenn.edu
215-200-2312
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Bluestar Silicones Launches a New Range of Silbione(R) TCS 7560 & 7561 Elastomers for Lingerie, Support Stockings and Medical Textile Applications
2. Orange Healthcare Joins the mHealth Alliance to Develop Mobile Health Solutions in West Africa
3. Visual Cues that Improve Walking for People with Movement Disorders - Study Shows Small Change in Arrangement Can Make a Big Difference in Improvement Gained
4. Insightra Medical Inc Gains CE Mark on the Freedom(TM) Inguinal Hernia Product Range
5. Rev. Michel Faulkner Seeks to Retire Charlie Rangel from New York's 15th Congressional Seat
6. New Heart Health Booster Supports Blood Pressure in the Normal Range*
7. Good Bye, Snake Oil! Grab your Orange Juice and Daily Virus Viper™ to Safeguard Against Micro-nutrient Deficiencies
8. Khanna Institute to Offer Newly FDA Approved Expanded Range of Intacs for Keratoconus
9. Strange Artifact Identified as Ancient Anti-Snoring Device
10. HealthCare Partners Medical Group Expands to Orange County. HealthCare Partners and Talbert Medical Group Join Forces
11. Dynowatt Offers Facebook Fans a Chance to See the Rangers and Astros Play for Texas Bragging Rights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... , ... Harris Communications, Inc., a leading provider of assistive technology for ... Deaf Seniors of America Conference, April 4-7 at the Hotel Westin Galleria in Houston. ... staff from Harris Communications and to try out the newest assistive devices available to ...
(Date:3/25/2017)... ... , ... Getting earned media coverage meaningful for Garden Media Group's clients is ... year, Garden Media aims to provide material helpful to clients’ goals and bottom lines. ... key messages to gain coveted media placements, Garden Media wows clients year-round. , ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... solutions for contaminated soil, dredged material, and hazardous and non-hazardous materials announced today ... Allentown, Pennsylvania. This acquisition will add four additional processing facilities and a ...
(Date:3/24/2017)... ... March 24, 2017 , ... Mediaplanet today ... conversation on the current obstacles facing infection prevention and offer strategies for the ... by these infections. , The print component of “Fighting Infection” is distributed ...
(Date:3/24/2017)... ... March 24, 2017 , ... Digital Scientists, a software innovation lab specializing in ... a Greenville, South Carolina location. The lab has set up shop at ... been working with South Carolina clients for years from our office here in Atlanta,” ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... and BOSTON , March 27, ... global pharmaceutical company and Paratek Pharmaceuticals, Inc. (Nasdaq: ... and commercialization of innovative therapies based upon tetracycline ... of sarecycline for the treatment of moderate to ... endpoints. Sarecycline is a once-daily, oral, narrow spectrum ...
(Date:3/27/2017)... 27, 2017  PhaseRx, Inc. (NASDAQ: PZRX), a ... liver diseases in children, today reported financial results ... December 31, 2016 and provided an update on ... to make progress during the fourth quarter of ... our non-human primate safety study, and with our lead ...
(Date:3/24/2017)... , Mar 24, 2017 Research ... Therapy Manufacturing Market, 2017-2027" report to their offering. ... The Cell ... the rapidly growing market of cell therapy manufacturing and focuses ... manufacturing facilities. These therapies are anticipated to emerge as viable ...
Breaking Medicine Technology: